• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.740 +0.240 (+5.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,024,801
Open 4.470
Bid (Size) 4.710 (900)
Ask (Size) 4.760 (3,000)
Prev. Close 4.500
Today's Range 4.410 - 4.770
52wk Range 2.705 - 5.100
Shares Outstanding 99,161,234
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
January 12, 2026
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
January 09, 2026
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
Via PredictStreet
Topics Initial Public Offering Intellectual Property

Performance

YTD
-0.6%
-0.6%
1 Month
-4.2%
-4.2%
3 Month
+10.7%
+10.7%
6 Month
+46.3%
+46.3%
1 Year
+41.5%
+41.5%

More News

Read More
News headline image
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum ↗
October 21, 2025
Via Chartmill
News headline image
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
October 07, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus (ABUS) Q2 Revenue Surges 529% ↗
August 06, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
June 25, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
May 07, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
April 23, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
March 27, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
March 03, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
February 25, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Provides 2025 Corporate and Financial Update
January 13, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
December 03, 2024
From Whitefort Capital Management, LP
Via Business Wire
News headline image
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
November 26, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
November 20, 2024
Via Benzinga
News headline image
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
November 15, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
November 15, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Arbutus to Present at Jefferies London Healthcare Conference
November 14, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
October 23, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
October 15, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine ↗
October 03, 2024
Via Benzinga
Topics Intellectual Property

Frequently Asked Questions

Is Arbutus Biopharma Corporation - Common Stock publicly traded?
Yes, Arbutus Biopharma Corporation - Common Stock is publicly traded.
What exchange does Arbutus Biopharma Corporation - Common Stock trade on?
Arbutus Biopharma Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arbutus Biopharma Corporation - Common Stock?
The ticker symbol for Arbutus Biopharma Corporation - Common Stock is ABUS on the Nasdaq Stock Market
What is the current price of Arbutus Biopharma Corporation - Common Stock?
The current price of Arbutus Biopharma Corporation - Common Stock is 4.740
When was Arbutus Biopharma Corporation - Common Stock last traded?
The last trade of Arbutus Biopharma Corporation - Common Stock was at 01/13/26 04:00 PM ET
What is the market capitalization of Arbutus Biopharma Corporation - Common Stock?
The market capitalization of Arbutus Biopharma Corporation - Common Stock is 470.02M
How many shares of Arbutus Biopharma Corporation - Common Stock are outstanding?
Arbutus Biopharma Corporation - Common Stock has 470M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap